These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33850265)

  • 41. Overexpression of SCAMP3 is an indicator of poor prognosis in hepatocellular carcinoma.
    Zhang X; Sheng J; Zhang Y; Tian Y; Zhu J; Luo N; Xiao C; Li R
    Oncotarget; 2017 Dec; 8(65):109247-109257. PubMed ID: 29312605
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Understanding the MIG6-EGFR Signaling Axis in Lung Tumorigenesis.
    Izumchenko E; Sidransky D
    Cancer Discov; 2015 May; 5(5):472-4. PubMed ID: 25941338
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activation of the signal transducer and activator of transcription 3 pathway up-regulates estrogen receptor-beta expression in lung adenocarcinoma cells.
    Wang HC; Yeh HH; Huang WL; Lin CC; Su WP; Chen HH; Lai WW; Su WC
    Mol Endocrinol; 2011 Jul; 25(7):1145-58. PubMed ID: 21546410
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Quantitative targeted proteomic analysis of potential markers of tyrosine kinase inhibitor (TKI) sensitivity in EGFR mutated lung adenocarcinoma.
    Awasthi S; Maity T; Oyler BL; Qi Y; Zhang X; Goodlett DR; Guha U
    J Proteomics; 2018 Oct; 189():48-59. PubMed ID: 29660496
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cetuximab Inhibits T790M-Mediated Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in a Lung Adenocarcinoma Patient-Derived Xenograft Mouse Model.
    Martin P; Stewart E; Pham NA; Mascaux C; Panchal D; Li M; Kim L; Sakashita S; Wang D; Sykes J; Friess T; Shepherd FA; Liu G; Tsao MS
    Clin Lung Cancer; 2016 Sep; 17(5):375-383.e2. PubMed ID: 26926157
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Curcumin induces EGFR degradation in lung adenocarcinoma and modulates p38 activation in intestine: the versatile adjuvant for gefitinib therapy.
    Lee JY; Lee YM; Chang GC; Yu SL; Hsieh WY; Chen JJ; Chen HW; Yang PC
    PLoS One; 2011; 6(8):e23756. PubMed ID: 21858220
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Desmoglein-2 modulates tumor progression and osimertinib drug resistance through the EGFR/Src/PAK1 pathway in lung adenocarcinoma.
    Jin R; Wang X; Zang R; Liu C; Zheng S; Li H; Sun N; He J
    Cancer Lett; 2020 Jul; 483():46-58. PubMed ID: 32272148
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Morphine-induced epidermal growth factor pathway activation in non-small cell lung cancer.
    Fujioka N; Nguyen J; Chen C; Li Y; Pasrija T; Niehans G; Johnson KN; Gupta V; Kratzke RA; Gupta K
    Anesth Analg; 2011 Dec; 113(6):1353-64. PubMed ID: 22003224
    [TBL] [Abstract][Full Text] [Related]  

  • 49. STAMBP promotes lung adenocarcinoma metastasis by regulating the EGFR/MAPK signaling pathway.
    Xu H; Yang X; Xuan X; Wu D; Zhang J; Xu X; Zhao Y; Ma C; Li D
    Neoplasia; 2021 Jun; 23(6):607-623. PubMed ID: 34102455
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS.
    Guha U; Chaerkady R; Marimuthu A; Patterson AS; Kashyap MK; Harsha HC; Sato M; Bader JS; Lash AE; Minna JD; Pandey A; Varmus HE
    Proc Natl Acad Sci U S A; 2008 Sep; 105(37):14112-7. PubMed ID: 18776048
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 52. The Rak/Frk tyrosine kinase associates with and internalizes the epidermal growth factor receptor.
    Jin L; Craven RJ
    Oncogene; 2014 Jan; 33(3):326-35. PubMed ID: 23318459
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Epidermal growth factor receptor phosphorylation sites Ser991 and Tyr998 are implicated in the regulation of receptor endocytosis and phosphorylations at Ser1039 and Thr1041.
    Tong J; Taylor P; Peterman SM; Prakash A; Moran MF
    Mol Cell Proteomics; 2009 Sep; 8(9):2131-44. PubMed ID: 19531499
    [TBL] [Abstract][Full Text] [Related]  

  • 54. DOK2 inhibits EGFR-mutated lung adenocarcinoma.
    Berger AH; Chen M; Morotti A; Janas JA; Niki M; Bronson RT; Taylor BS; Ladanyi M; Van Aelst L; Politi K; Varmus HE; Pandolfi PP
    PLoS One; 2013; 8(11):e79526. PubMed ID: 24255704
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low-Dose Nicotine Activates EGFR Signaling via α5-nAChR and Promotes Lung Adenocarcinoma Progression.
    Wang ML; Hsu YF; Liu CH; Kuo YL; Chen YC; Yeh YC; Ho HL; Wu YC; Chou TY; Wu CW
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957649
    [TBL] [Abstract][Full Text] [Related]  

  • 56. NF-κB signaling is activated and confers resistance to apoptosis in three-dimensionally cultured EGFR-mutant lung adenocarcinoma cells.
    Sakuma Y; Yamazaki Y; Nakamura Y; Yoshihara M; Matsukuma S; Koizume S; Miyagi Y
    Biochem Biophys Res Commun; 2012 Jul; 423(4):667-71. PubMed ID: 22695117
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Deguelin suppresses non-small cell lung cancer by inhibiting EGFR signaling and promoting GSK3β/FBW7-mediated Mcl-1 destabilization.
    Gao F; Yu X; Li M; Zhou L; Liu W; Li W; Liu H
    Cell Death Dis; 2020 Feb; 11(2):143. PubMed ID: 32081857
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells.
    Sato M; Vaughan MB; Girard L; Peyton M; Lee W; Shames DS; Ramirez RD; Sunaga N; Gazdar AF; Shay JW; Minna JD
    Cancer Res; 2006 Feb; 66(4):2116-28. PubMed ID: 16489012
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Elevated expression of Fn14 in non-small cell lung cancer correlates with activated EGFR and promotes tumor cell migration and invasion.
    Whitsett TG; Cheng E; Inge L; Asrani K; Jameson NM; Hostetter G; Weiss GJ; Kingsley CB; Loftus JC; Bremner R; Tran NL; Winkles JA
    Am J Pathol; 2012 Jul; 181(1):111-20. PubMed ID: 22634180
    [TBL] [Abstract][Full Text] [Related]  

  • 60. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
    Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
    Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.